Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hereditary angioedema
Biotech
With new data in hand, Astria makes ph. 3 wish on shooting star
Astria Therapeutics is planning a phase 3 launch for its star monoclonal antibody after an early phase 1b/2 data drop in hereditary angioedema.
Gabrielle Masson
Mar 25, 2024 10:46am
KalVista's persistence with sebetralstat pays off in ph. 3 win
Feb 13, 2024 6:30am
Ionis’ HAE drug wins in phase 3 setting up approval run to FDA
Jan 22, 2024 9:34am
FDA lifts remaining hold on Pharvaris’ HAE drug
Jan 22, 2024 7:32am
Otsuka pays Ionis $65M for European rights to rare disease drug
Dec 19, 2023 10:18am
Intellia fills gene editing trial outside US after FDA request
Aug 3, 2023 9:23am